Vicarious Surgical Reports Third Quarter 2023 Financial Results Vicarious Surgical Inc. (“Vicarious Surgical” or the “Company”) (NYSE: RBOT, RBOT WS), a next-generation robotics technology company seeking to improve patient outcomes…
Oak Street Health, a network of value-based primary care centers for adults on Medicare and the only primary care provider to carry the AARP name, is now welcoming patients at the…
Novartis today announced new positive data from the Phase III REMIX-1 and REMIX-2 studies investigating remibrutinib – a highly selective, oral Bruton’s tyrosine kinase (BTK) inhibitor – in people with…
Beginning Jan. 1, 2024, Optum Rx will place eight preferred insulin products on tier one of standard commercial formularies, limiting out-of-pocket spend to $35 or less. Optum Rx, a pharmacy…
Cardinal Health (NYSE: CAH) announced today the U.S. launch of its SmartGown™ EDGE Breathable Surgical Gown with ASSIST™ Instrument Pockets, created to provide surgical teams safe and convenient instrument access…
CVS Health Foundation today announced it has awarded $3 million in grants over five years to advance mental health equity to Healthy Start Coalition of Hillsborough County in Florida, Meadows…
Baxter International Inc. (NYSE:BAX), a global innovator in kidney care and vital organ support, announced today new data indicating Baxter’s Sharesource remote patient management (RPM) digital platform, when used with an automated…
Chemed Corporation (NYSE: CHE) – After more than three decades, Executive Vice President and Chief Financial Officer David P. Williams has announced that he will retire as Chemed’s Chief Financial Officer as of December…
Doximity, Inc. (NYSE: DOCS), the leading digital platform for U.S. medical professionals, today announced DocDefender, a free service for physicians that tracks down and eliminates their personal contact information from public…
Baxter International Inc. (NYSE:BAX), a global medtech leader, today reported results for the third quarter of 2023. “Baxter continues to successfully execute upon the slate of strategic actions we announced…
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the Phase 3 KEYNOTE-564 trial evaluating KEYTRUDA, Merck’s anti-PD-1 therapy, met its key secondary…
Novartis today announced positive topline results from the interim analysis of the ongoing pivotal Phase III ALIGN study (NCT04573478) of atrasentan, an oral endothelin A receptor antagonist (ERA), in patients…
